In-patient neurosurgical tumor treatments for malignant glioma patients in Germany.
Age
Fluorescence-guided resection
Glioblastoma
Malignant glioma
Monitoring
Mortality
Palliative care
Surgery
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
21
06
2024
accepted:
18
07
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
aheadofprint
Résumé
Treatment for malignant gliomas involves multiple disciplines, including neurosurgery, radiation therapy, medical and neuro-oncology, and palliative medicine, with function-preserving neurosurgical tumor removal being crucial. However, real-world data on hospital cases, treatment types, especially regarding surgical approaches, and the associated complication and mortality rates in Germany are lacking. We analyzed data on hospital cases involving malignant gliomas (ICD-10-GM code C71) from the German §21 Hospital Remuneration Act, provided by the Institute for the Hospital Remuneration System (InEK GmbH), from 2019 to 2022. Our focus was on neuro-oncological operations defined by the German Cancer Society (DKG) and included specific operation and procedure (OPS) codes. From 2019 to 2022, there were 101,192 hospital cases involving malignant gliomas in Germany. Neurosurgical tumor removal was performed in 27,193 cases (26.9%). Microsurgical techniques were used in 95% of surgeries, intraoperative navigation systems in 84%, fluorescence-guided surgeries in 45.6%, and intraoperative neurophysiological monitoring (IONM) in 46.4%. Surgical or medical complications occurred in 2903 cases (10.7%). The hospital mortality rate was 2.7%. Mortality was significantly higher in patients aged 65 and older (Odds ratio 2.9, p < 0.0001), and lower in cases using fluorescence-guided procedures (Odds ratio 0.8, p = 0.015) and IONM (Odds ratio 0.5, p < 0.0001). Over the course of 4 years, over 100,000 hospital cases involving adult patients diagnosed with malignant gliomas were treated in Germany, with 27,193 cases undergoing tumor removal using various modern surgical techniques. The hospital mortality rate was 2.7%.
Identifiants
pubmed: 39390195
doi: 10.1007/s11060-024-04784-2
pii: 10.1007/s11060-024-04784-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M (2024) PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a Report of the RANO Group. Lancet Oncol 25:e29–e41. https://doi.org/10.1016/s1470-2045(23)00525-9
doi: 10.1016/s1470-2045(23)00525-9
pubmed: 38181810
Barker FG II, Curry WT Jr, Carter BS (2005) Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care. Neurooncology 7:49–63. https://doi.org/10.1215/S1152851704000146
doi: 10.1215/S1152851704000146
Baumgarten P, Prange G, Kamp MA, Monden D, Neef V, Schwarzer F, Dubinski D, Dinc N, Weber KJ, Czabanka M, Hattingen E, Ronellenfitsch MW, Steinbach JP, Senft C (2023) Treatment of very elderly glioblastoma patients >/= 75 years of age: whom to treat. J Neurooncol 165:509–515. https://doi.org/10.1007/s11060-023-04518-w
doi: 10.1007/s11060-023-04518-w
pubmed: 38032426
pmcid: 10752837
Berger K, Turowski B, Felsberg J, Malzkorn B, Reifenberger G, Steiger HJ, Budach W, Haussmann J, Knipps J, Rapp M, Hanggi D, Sabel M, Mijderwijk HJ, Kamp MA (2021) Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. J Cancer Res Clin Oncol 147:253–262. https://doi.org/10.1007/s00432-020-03334-3
doi: 10.1007/s00432-020-03334-3
pubmed: 32748120
Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343. https://doi.org/10.1200/JCO.2012.43.2674
doi: 10.1200/JCO.2012.43.2674
pubmed: 23071247
De Witt Hamer PC, Ho VKY, Zwinderman AH, Ackermans L, Ardon H, Boomstra S, Bouwknegt W, van den Brink WA, Dirven CM, van der Gaag NA, van der Veer O, Idema AJS, Kloet A, Koopmans J, Ter Laan M, Verstegen MJT, Wagemakers M, Robe P, Quality Registry Neuro Surgery Glioblastoma Working Group from the Dutch Society of Neurosurgery (2019) Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro Surgery. J Neurooncol 144:313–323. https://doi.org/10.1007/s11060-019-03229-5
doi: 10.1007/s11060-019-03229-5
pubmed: 31236819
pmcid: 6700042
De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS (2012) Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 30:2559–2565. https://doi.org/10.1200/JCO.2011.38.4818
doi: 10.1200/JCO.2011.38.4818
pubmed: 22529254
Ferrell B, Chung V, Hughes MT, Koczywas M, Azad NS, Ruel NH, Knight L, Cooper RS, Smith TJ (2021) A palliative care intervention for patients on Phase 1 studies. J Palliat Med 24:846–856. https://doi.org/10.1089/jpm.2020.0597
doi: 10.1089/jpm.2020.0597
pubmed: 33103938
pmcid: 8147498
Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, Firn JI, Paice JA, Peppercorn JM, Phillips T, Stovall EL, Zimmermann C, Smith TJ (2017) Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:96–112. https://doi.org/10.1200/JCO.2016.70.1474
doi: 10.1200/JCO.2016.70.1474
pubmed: 28034065
Fink L, van Oorschot B, von Sass C, Dibue M, Foster MT, Golla H, Goldbrunner R, Senft C, Lawson McLean A, Hellmich M, Dinc N, Voltz R, Melching H, Jungk C, Kamp MA (2024) Palliative care for in-patient malignant glioma patients in Germany. J Neurooncol 167:323–338. https://doi.org/10.1007/s11060-024-04611-8
doi: 10.1007/s11060-024-04611-8
pubmed: 38506960
pmcid: 11023986
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M (2019) Lomustine–temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393:678–688. https://doi.org/10.1016/s0140-6736(18)31791-4
doi: 10.1016/s0140-6736(18)31791-4
pubmed: 30782343
Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F, Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Thon N, Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R, Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS, Esquenazi Y, Tonn J-C (2024) Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: a complementary report of the RANO Resect Group. Neuro-oncology 26:584–586. https://doi.org/10.1093/neuonc/noad237
doi: 10.1093/neuonc/noad237
pubmed: 38164632
Lassen B, Helseth E, Ronning P, Scheie D, Johannesen TB, Maehlen J, Langmoen IA, Meling TR (2011) Surgical mortality at 30 days and complications leading to recraniotomy in 2630 consecutive craniotomies for intracranial tumors. Neurosurgery 68:1259–1268; discussion 1268–1259. https://doi.org/10.1227/NEU.0b013e31820c0441
Lofgren D, Valachis A, Olivecrona M (2022) Risk for morbidity and mortality after neurosurgery in older patients with high grade gliomas—a retrospective population based study. BMC Geriatr 22:805. https://doi.org/10.1186/s12877-022-03478-6
doi: 10.1186/s12877-022-03478-6
pubmed: 36253725
pmcid: 9575213
Long DM, Gordon T, Bowman H, Etzel A, Burleyson G, Betchen S, Garonzik IM, Brem H (2003) Outcome and cost of craniotomy performed to treat tumors in regional academic referral centers. Neurosurgery 52:1056–1065. https://doi.org/10.1227/01.Neu.0000057745.48813.93
doi: 10.1227/01.Neu.0000057745.48813.93
pubmed: 12699547
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, Phase 3 trial. Lancet Oncol 13:916–926. https://doi.org/10.1016/s1470-2045(12)70265-6
doi: 10.1016/s1470-2045(12)70265-6
pubmed: 22877848
Mijderwijk HJ, Nieboer D, Incekara F, Berger K, Steyerberg EW, van den Bent MJ, Reifenberger G, Hanggi D, Smits M, Senft C, Rapp M, Sabel M, Voss M, Forster MT, Kamp MA (2022) Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. J Neurosurg. https://doi.org/10.3171/2021.10.JNS211261
doi: 10.3171/2021.10.JNS211261
pubmed: 35171829
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro-oncology 23:iii1–iii105. https://doi.org/10.1093/neuonc/noab200
doi: 10.1093/neuonc/noab200
pubmed: 34608945
pmcid: 8491279
Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Ruda R, Marosi C, Le Rhun E, Grant R, Oliver K, Oberg I, Bulbeck HJ, Rooney AG, Henriksson R, Pasman HRW, Oberndorfer S, Weller M, Taphoorn MJB, European Association of Neuro-Oncology Palliative Care Task Force (2017) European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol 18:e330–e340. https://doi.org/10.1016/S1470-2045(17)30345-5
doi: 10.1016/S1470-2045(17)30345-5
pubmed: 28593859
Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP, Trial Investigators (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. https://doi.org/10.1056/NEJMoa1611977
doi: 10.1056/NEJMoa1611977
pubmed: 28296618
Poppe JP, Machegger L, Steinbacher J, Stefanits H, Eisschiel S, Gruber A, Demetz M, Ladisich B, Kraus TFJ, Weis S, Spiegl-Kreinecker S, Romagna A, Griessenauer CJ, Jahromi BR, Rautalin I, Niemela M, Korja M, Schwartz C (2023) Surgeon experience in glioblastoma surgery of the elderly—a multicenter, retrospective cohort study. J Neurooncol 161:563–572. https://doi.org/10.1007/s11060-023-04252-3
doi: 10.1007/s11060-023-04252-3
pubmed: 36719614
pmcid: 9992256
Saunders C (1975) The care of the dying patient and his family. Doc Med Ethics. https://doi.org/10.1080/13520806.1972.11759235
doi: 10.1080/13520806.1972.11759235
pubmed: 11662275
Schwarzkopf D, Rose N, Fleischmann-Struzek C, Boden B, Dorow H, Edel A, Friedrich M, Gonnert FA, Gotz J, Grundling M, Heim M, Holbeck K, Jaschinski U, Koch C, Kunzer C, Le Ngoc K, Lindau S, Mehlmann NB, Meschede J, Meybohm P, Ouart D, Putensen C, Sander M, Schewe JC, Schlattmann P, Schmidt G, Schneider G, Spies C, Steinsberger F, Zacharowski K, Zinn S, Reinhart K (2023) Understanding the biases to sepsis surveillance and quality assurance caused by inaccurate coding in administrative health data. Infection. https://doi.org/10.1007/s15010-023-02091-y
doi: 10.1007/s15010-023-02091-y
pubmed: 37684496
pmcid: 10954942
Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V (2011) Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 12:997–1003. https://doi.org/10.1016/s1470-2045(11)70196-6
doi: 10.1016/s1470-2045(11)70196-6
pubmed: 21868284
Stummer W, Kamp MA (2009) The importance of surgical resection in malignant glioma. Curr Opin Neurol 22:645–649. https://doi.org/10.1097/WCO.0b013e3283320165
doi: 10.1097/WCO.0b013e3283320165
pubmed: 19738467
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. https://doi.org/10.1016/s1470-2045(06)70665-9
doi: 10.1016/s1470-2045(06)70665-9
pubmed: 16648043
Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576; discussion 564–576. https://doi.org/10.1227/01.neu.0000317304.31579.17
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
doi: 10.1056/NEJMoa043330
pubmed: 15758009
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM (2017) Interim results from the CATNON trial (EORTC Study 26053–22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 390:1645–1653. https://doi.org/10.1016/S0140-6736(17)31442-3
doi: 10.1016/S0140-6736(17)31442-3
pubmed: 28801186
pmcid: 5806535
van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG (2021) Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC Study 26053–22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22:813–823. https://doi.org/10.1016/S1470-2045(21)00090-5
doi: 10.1016/S1470-2045(21)00090-5
pubmed: 34000245
pmcid: 8191233
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, STROBE Initiative (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X
doi: 10.1016/S0140-6736(07)61602-X
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Ruda R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170–186. https://doi.org/10.1038/s41571-020-00447-z
doi: 10.1038/s41571-020-00447-z
pubmed: 33293629
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715. https://doi.org/10.1016/s1470-2045(12)70164-x
doi: 10.1016/s1470-2045(12)70164-x
pubmed: 22578793